Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 6/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13728795 | 1.00 | MMP13 (0.49) | MMP13ROCK2ROCK1ALDH1A1MAPK1 | |
| SCHEMBL13837384 | 1.00 | MMP13 (0.49) | MMP13ROCK2ROCK1ALDH1A1MAPK1 | |
| SCHEMBL13729214 | 0.89 | MMP13 (0.51) | MMP13ROCK2ROCK1ALDH1A1MAPK1 | |
| SCHEMBL13837553 | 0.89 | MMP13 (0.47) | MMP13 | |
| SCHEMBL13730528 | 0.89 | MMP13 (0.47) | MMP13 | |
| SCHEMBL13730530 | 0.89 | MMP13 (0.47) | MMP13 | |
| SCHEMBL13837460 | 0.86 | MMP13 (0.45) | MMP13MAPK1 | |
| SCHEMBL14632633 | 0.84 | MAPT (0.53) | ALDH1A1HTTL3MBTL1MEN1KMT2A | |
| SCHEMBL14632636 | 0.84 | MAPT (0.53) | ALDH1A1HTTL3MBTL1MEN1KMT2A | |
| SCHEMBL13837455 | 0.84 | MAPT (0.53) | ALDH1A1HTTL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBVIE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9029409-B2 | Isoxazolines as therapeutic agents | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2704712-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | AbbVie Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012151158-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | CYP3A7, CYP11B2, CYP11B1 | MMP13 1996/4885ROCK2 4210/4885ROCK1 4035/4885 |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | CYP3A7, CYP11B2, CYP11B1 | MMP13 1996/4885ROCK2 4210/4885ROCK1 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.